{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:50:43Z","timestamp":1789339843861,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejoncologynursing.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejon.2024.102540","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T05:05:10Z","timestamp":1709096710000},"page":"102540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Acute, long-term or non-vincristine-induced peripheral neuropathy among non-Hodgkin lymphoma survivors: Symptoms, daily activities, functional status, and quality of life"],"prefix":"10.1016","volume":"69","author":[{"given":"Yu-Chen","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeur-Hur","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Tsang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Lin Jerry","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Hsiang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejon.2024.102540_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.ejon.2024.102540_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.NNR.0000289503.22414.79","article-title":"Background noise: the experience of chemotherapy-induced peripheral neuropathy","volume":"56","author":"Bakitas","year":"2007","journal-title":"Nurs. Res."},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib3","first-page":"2411","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.ejon.2024.102540_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/pmt-2018-0020","article-title":"An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy","volume":"8","author":"Boyette-Davis","year":"2018","journal-title":"Pain Manag."},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib5","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ejon.2024.102540_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.6771","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"5","author":"Brown","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ejon.2024.102540_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol Ther"},{"issue":"2","key":"10.1016\/j.ejon.2024.102540_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/toxics11020104","article-title":"Self-reported assessment of the socio-economic impact of anticancer chemotherapy-related neurotoxicity","volume":"11","author":"Cavaletti","year":"2023","journal-title":"Toxics"},{"issue":"3","key":"10.1016\/j.ejon.2024.102540_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/1467-8721.ep10768783","article-title":"Statistical power analysis","volume":"1","author":"Cohen","year":"1992","journal-title":"Curr. Dir. Psychol. Sci."},{"key":"10.1016\/j.ejon.2024.102540_bib10","series-title":"Applied Nonparametric Statistics","author":"Daniel","year":"1990"},{"issue":"3","key":"10.1016\/j.ejon.2024.102540_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/00401706.1964.10490181","article-title":"Multiple comparisons using rank sums","volume":"6","author":"Dunn","year":"1964","journal-title":"Technometrics"},{"issue":"4","key":"10.1016\/j.ejon.2024.102540_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/1078155219870840","article-title":"Peripheral neuropathy in non-Hodgkin\u2019s lymphoma patients receiving vincristine with and without aprepitant\/fosaprepitant","volume":"26","author":"Edwards","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejon.2024.102540_bib13","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2147\/JPR.S409580","article-title":"Nursing dilemmas in chemotherapy-induced peripheral neuropathy: a qualitative study of a tertiary hospital in China","volume":"16","author":"Fan","year":"2023","journal-title":"J. Pain Res."},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3109\/02841869109092444","article-title":"Muscle cramps associated with vincristine therapy","volume":"30","author":"Haim","year":"1991","journal-title":"Acta Oncol."},{"issue":"10","key":"10.1016\/j.ejon.2024.102540_bib15","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","article-title":"Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas","volume":"73","author":"Haim","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ejon.2024.102540_bib16","year":"2018"},{"issue":"18","key":"10.1016\/j.ejon.2024.102540_bib17","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejon.2024.102540_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3747\/co.21.1984","article-title":"The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients","volume":"21","author":"Hong","year":"2014","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib19","article-title":"Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: a cross-sectional study","volume":"99","author":"Hsu","year":"2020","journal-title":"Medicine (Baltim.)"},{"issue":"10","key":"10.1016\/j.ejon.2024.102540_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275648","article-title":"A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy","volume":"17","author":"Ibrahim","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejon.2024.102540_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5530\/jyp.2016.3.12","article-title":"Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients","volume":"8","author":"Imam","year":"2016","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.ejon.2024.102540_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2021.102041","article-title":"Experiences and perspectives of suffering in cancer: a qualitative systematic review","volume":"54","author":"Iskandar","year":"2021","journal-title":"Eur. J. Oncol. Nurs."},{"issue":"4","key":"10.1016\/j.ejon.2024.102540_bib23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MPH.0000000000000825","article-title":"Electrophysiological studies to detect peripheral neuropathy in children treated with vincristine","volume":"39","author":"Kavcic","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.ejon.2024.102540_bib24","volume":"116","author":"Kim","year":"2010","journal-title":"Blood"},{"issue":"260","key":"10.1016\/j.ejon.2024.102540_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J. Am. Stat. Assoc."},{"issue":"10","key":"10.1016\/j.ejon.2024.102540_bib26","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European organization for research and treatment of cancer QLQ-CIPN20 questionnaire","volume":"22","author":"Lavoie Smith","year":"2013","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF03259853","article-title":"Vincristine neurotoxicity. Pathophysiology and management","volume":"1","author":"Legha","year":"1986","journal-title":"Med. Toxicol."},{"key":"10.1016\/j.ejon.2024.102540_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine-induced peripheral neuropathy: a mini-review","volume":"81","author":"Li","year":"2020","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/j.ejon.2024.102540_bib29","article-title":"Comparing and validating simple measures of patient-reported peripheral neuropathy for oncology clinical trials: NCCTG N0897 (alliance) A pooled analysis of 2440 patients","volume":"2","author":"Liu","year":"2015","journal-title":"SOJ Anesthesiol Pain Manag"},{"issue":"18","key":"10.1016\/j.ejon.2024.102540_bib30","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.2013.54.2050","article-title":"Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?","volume":"32","author":"Mandelblatt","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejon.2024.102540_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jcrpr.2017.03.005","article-title":"Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment","volume":"4","author":"Marshall","year":"2017","journal-title":"Journal of Cancer Research and Practice"},{"issue":"7","key":"10.1016\/j.ejon.2024.102540_bib32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/IGC.0000000000001320","article-title":"The influence of chemotherapy-induced peripheral neuropathy on quality of life of gynecologic cancer survivors","volume":"28","author":"Matsuoka","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejon.2024.102540_bib33","series-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","author":"Network","year":"2023"},{"issue":"4","key":"10.1016\/j.ejon.2024.102540_bib34","first-page":"252","article-title":"Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy","volume":"6","author":"Okada","year":"2014","journal-title":"J. Clin. Med. Res."},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2024.102540_bib36","article-title":"Clinical outcomes of patients with B-cell non-hodgkin lymphoma in real-world settings: findings from the hemato-oncology Latin America observational registry study","volume":"8","author":"Pavlovsky","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"10.1016\/j.ejon.2024.102540_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/nur.20147","article-title":"The content validity index: are you sure you know what's being reported? Critique and recommendations","volume":"29","author":"Polit","year":"2006","journal-title":"Res. Nurs. Health"},{"issue":"8","key":"10.1016\/j.ejon.2024.102540_bib38","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejon.2024.102540_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01050259","article-title":"Long-term effects of vincristine on the peripheral nervous system","volume":"15","author":"Postma","year":"1993","journal-title":"J. Neuro Oncol."},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib40","first-page":"5055","article-title":"Physical impairments, sensory disturbance, and functional ability in a cancer patient with and without chemotherapy-induced peripheral neuropathy symptoms","volume":"30","author":"Rattanakrong","year":"2022","journal-title":"Support. Care Cancer"},{"issue":"4","key":"10.1016\/j.ejon.2024.102540_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1212\/WNL.19.4.367","article-title":"Vincristine-induced neuropathy. A clinical study of fifty leukemic patients","volume":"19","author":"Sandler","year":"1969","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ejon.2024.102540_bib42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12185-020-02832-x","article-title":"Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy","volume":"111","author":"Sawaki","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.ejon.2024.102540_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0885-3924(91)90522-6","article-title":"Muscle cramps in the cancer patient: causes and treatment","volume":"6","author":"Siegal","year":"1991","journal-title":"J. Pain Symptom Manag."},{"issue":"4","key":"10.1016\/j.ejon.2024.102540_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/0284186X.2018.1556804","article-title":"Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy","volume":"58","author":"Soveri","year":"2019","journal-title":"Acta Oncol."},{"issue":"1","key":"10.1016\/j.ejon.2024.102540_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11764-021-00997-w","article-title":"A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms","volume":"17","author":"Tanay","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"8","key":"10.1016\/j.ejon.2024.102540_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26471","article-title":"Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia","volume":"64","author":"Tay","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.ejon.2024.102540_bib47","first-page":"583","article-title":"Falls in persons with chemotherapy-induced peripheral neuropathy","volume":"20","author":"Tofthagen","year":"2012","journal-title":"Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.ejon.2024.102540_bib48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1179\/1607845412Y.0000000022","article-title":"Guidelines on obtaining consent for systemic anti-cancer therapy in adults","volume":"17","author":"Treleaven","year":"2012","journal-title":"Hematology"},{"issue":"22","key":"10.1016\/j.ejon.2024.102540_bib49","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1002\/cam4.4328","article-title":"Chemotherapy-induced peripheral neuropathy in African American cancer survivors: risk factors and quality of life outcomes","volume":"10","author":"Trendowski","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejon.2024.102540_bib50","article-title":"Coping with and self-management of chronic painful chemotherapy-induced peripheral neuropathy: a qualitative study among cancer survivors","author":"van de Graaf","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"6","key":"10.1016\/j.ejon.2024.102540_bib51","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.WNL.0000154642.45474.28","article-title":"Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening","volume":"64","author":"Verstappen","year":"2005","journal-title":"Neurology"}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388924000383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388924000383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T20:28:14Z","timestamp":1761424094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388924000383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"alternative-id":["S1462388924000383"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2024.102540","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute, long-term or non-vincristine-induced peripheral neuropathy among non-Hodgkin lymphoma survivors: Symptoms, daily activities, functional status, and quality of life","name":"articletitle","label":"Article Title"},{"value":"European Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejon.2024.102540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102540"}}